Full Text Journal Articles by
Author Sarah W Read

Advertisement

Find full text journal articles








Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials.

Timothy G Buchman, Ruxandra Draghia-Akli, Stacey J Adam, Neil R Aggarwal, Joshua P Fessel, Elizabeth S Higgs, Joseph P Menetski, Sarah W Read, Eric A Hughes, ,

Given the urgent need for coronavirus disease 2019 therapeutics, early in the pandemic the Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership rapidly designed a unique therapeutic agent intake and assessment process for candidate treatments of coronavirus disease 2019. These treatments included antivirals, immune modulators, severe acute ... Read more >>

Crit Care Med (Critical care medicine)
[2021, 49(11):1963-1973]

Cited: 0 times

View full text PDF listing >>



Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics.

Lisa LaVange, Stacey J Adam, Judith S Currier, Elizabeth S Higgs, Lora A Reineck, Eric A Hughes, Sarah W Read, ,

Working in an unprecedented time frame, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership developed and launched 9 master protocols between 14 April 2020 and 31 May 2021 to allow for the coordinated and efficient evaluation of multiple investigational therapeutic agents for COVID-19. The ACTIV master protocols were ... Read more >>

Ann Intern Med (Annals of internal medicine)
[2021, 174(9):1293-1300]

Cited: 2 times

View full text PDF listing >>



Advertisement

Therapy for Early COVID-19: A Critical Need.

Peter S Kim, Sarah W Read, Anthony S Fauci,

JAMA (JAMA)
[2020, 324(21):2149-2150]

Cited: 31 times

View full text PDF listing >>



2019: A Banner Year for Tuberculosis Research.

Robert W Eisinger, Alan C Embry, Sarah W Read, Anthony S Fauci,

This article outlines the significant scientific progress reported in 2019 that has led to the development of new drugs and therapeutic regimens, vaccine candidates, and diagnostics for the prevention and treatment of tuberculosis. In 2020, it will be important to build on this momentum and continue to advance basic and ... Read more >>

J Infect Dis (The Journal of infectious diseases)
[2020, 222(11):1768-1771]

Cited: 3 times

View full text PDF listing >>



Opportunistic Infections and Mortality: Still Room for Improvement.

Henry Masur, Sarah W Read,

J Infect Dis (The Journal of infectious diseases)
[2015, 212(9):1348-1350]

Cited: 5 times

View full text PDF listing >>



Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.

Allan R Tenorio, Ellen S Chan, Ronald J Bosch, Bernard J C Macatangay, Sarah W Read, Suria Yesmin, Babafemi Taiwo, David M Margolis, Jeffrey M Jacobson, Alan L Landay, Cara C Wilson, ,

<h4>Background</h4>Rifaximin, a nonabsorbable antibiotic that decreases lipopolysaccharide (LPS) in cirrhotics, may decrease the elevated levels of microbial translocation, T-cell activation and inflammation in human immunodeficiency virus (HIV)-positive immune nonresponders to antiretroviral therapy (ART).<h4>Methods</h4>HIV-positive adults receiving ART for ≥96 weeks with undetectable viremia for ≥48 weeks and CD4(+) T-cell counts <350 ... Read more >>

J Infect Dis (The Journal of infectious diseases)
[2015, 211(5):780-790]

Cited: 33 times

View full text PDF listing >>



Progress toward curing HIV infections with hematopoietic stem cell transplantation.

Stephen T Smiley, Anjali Singh, Sarah W Read, Opendra K Sharma, Diana Finzi, Clifford Lane, Jeffrey S Rice,

Combination antiretroviral therapy can suppress human immunodeficiency virus (HIV) infection but cannot completely eradicate the virus. A major obstacle in the quest for a cure is the difficulty in targeting and measuring latently infected cells. To date, a single person seems to have been cured of HIV. Hematopoietic stem cell ... Read more >>

Clin Infect Dis (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America)
[2015, 60(2):292-297]

Cited: 5 times

View full text PDF listing >>



Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.

Netanya G Sandler, Xinyan Zhang, Ronald J Bosch, Nicholas T Funderburg, Andrew I Choi, Janet K Robinson, Derek M Fine, Robert W Coombs, Jeffrey M Jacobson, Alan L Landay, Daniel C Douek, Randall Tressler, Sarah W Read, Cara C Wilson, Steven G Deeks, Michael M Lederman, Rajesh T Gandhi, ,

<h4>Unlabelled</h4>Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who ... Read more >>

J Infect Dis (The Journal of infectious diseases)
[2014, 210(10):1549-1554]

Cited: 50 times

View full text PDF listing >>



Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.

Jonathan Z Li, Brad Chapman, Patrick Charlebois, Oliver Hofmann, Brian Weiner, Alyssa J Porter, Reshmi Samuel, Saran Vardhanabhuti, Lu Zheng, Joseph Eron, Babafemi Taiwo, Michael C Zody, Matthew R Henn, Daniel R Kuritzkes, Winston Hide, , Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Sarah W Read, Jennifer Janik, Debra S Meres, Michael M Lederman, Lori Mong-Kryspin, Karl E Shaw, Louis G Zimmerman, Randi Leavitt, Guy De La Rosa, Amy Jennings,

<h4>Background</h4>The impact of raltegravir-resistant HIV-1 minority variants (MVs) on raltegravir treatment failure is unknown. Illumina sequencing offers greater throughput than 454, but sequence analysis tools for viral sequencing are needed. We evaluated Illumina and 454 for the detection of HIV-1 raltegravir-resistant MVs.<h4>Methods</h4>A5262 was a single-arm study of raltegravir and darunavir/ritonavir ... Read more >>

PLoS One (PloS one)
[2014, 9(3):e90485]

Cited: 18 times

View full text PDF listing >>



Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

Babafemi Taiwo, Lu Zheng, Sebastien Gallien, Roy M Matining, Daniel R Kuritzkes, Cara C Wilson, Baiba I Berzins, Edward P Acosta, Barbara Bastow, Peter S Kim, Joseph J Eron, ,

<h4>Objective</h4>To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients.<h4>Design</h4>Phase IIb, single-arm, open-label, multicenter study.<h4>Methods</h4>One hundred and twelve antiretroviral-naive, HIV-1-infected patients received DRV/r 800/100 mg once daily and RAL 400 mg twice daily. Primary endpoint was virologic failure by week 24. Virologic failure was defined as confirmed viral ... Read more >>

AIDS (AIDS (London, England))
[2011, 25(17):2113-2122]

Cited: 98 times

View full text PDF listing >>



Decreases in IL-7 levels during antiretroviral treatment of HIV infection suggest a primary mechanism of receptor-mediated clearance.

Jessica N Hodge, Sharat Srinivasula, Zonghui Hu, Sarah W Read, Brian O Porter, Insook Kim, Joann M Mican, Chang Paik, Paula Degrange, Michele Di Mascio, Irini Sereti,

IL-7 is essential for T-cell homeostasis. Elevated serum IL-7 levels in lymphopenic states, including HIV infection, are thought to be due to increased production by homeostatic feedback, decreased receptor-mediated clearance, or both. The goal of this study was to understand how immune reconstitution through antiretroviral therapy (ART) in HIV(+) patients ... Read more >>

Blood (Blood)
[2011, 118(12):3244-3253]

Cited: 28 times

View full text PDF listing >>



CD4+ T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors.

Emily J Ciccone, Jamieson H Greenwald, Philip I Lee, Angélique Biancotto, Sarah W Read, Michael A Yao, Jessica N Hodge, William L Thompson, Stephen B Kovacs, Cheryl L Chairez, Stephen A Migueles, Joseph A Kovacs, Leonid B Margolis, Irini Sereti,

During acute human immunodeficiency virus (HIV) infection, there is a massive depletion of CD4(+) T cells in the gut mucosa that can be reversed to various degrees with antiretroviral therapy. Th17 cells have been implicated in mucosal immunity to extracellular bacteria, and preservation of this subset may support gut mucosal ... Read more >>

J Virol (Journal of virology)
[2011, 85(12):5880-5888]

Cited: 51 times

View full text PDF listing >>



The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients.

Sarah W Read, Emily J Ciccone, Peter J Mannon, Michael D Yao, Cheryl L Chairez, Richard T Davey, Joseph A Kovacs, Irini Sereti,

We sought to determine the effects of interleukin-2 administered in combination with antiretroviral therapy (ART) on CD4+ T cells in the gut. Lymphocytes from whole blood, colon, and terminal ileum of HIV-infected adults treated with interleukin-2 and ART or ART alone were examined. There were no differences between groups in ... Read more >>

J Acquir Immune Defic Syndr (Journal of acquired immune deficiency syndromes (1999))
[2011, 56(4):340-343]

Cited: 5 times

View full text PDF listing >>



Nanotechnology and HIV: potential applications for treatment and prevention.

Peter S Kim, Sarah W Read,

HIV/AIDS is a global pandemic and is the leading infectious cause of death among adults. Although antiretroviral (ARV) therapy has dramatically improved the quality of life and increased the life expectancy of those infected with HIV, life-long suppressive treatment is required and a cure for HIV infection remains elusive; frequency ... Read more >>

Wiley Interdiscip Rev Nanomed Nanobiotechnol (Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology)
[2010, 2(6):693-702]

Cited: 16 times

View full text PDF listing >>



The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.

Sarah W Read, Mary DeGrezia, Emily J Ciccone, Rebecca DerSimonian, Jeanette Higgins, Joseph W Adelsberger, Judith M Starling, Catherine Rehm, Irini Sereti,

<h4>Background</h4>The pathogenesis of immunodeficiency due to human immunodeficiency virus (HIV)-1 is incompletely understood, but immune activation is believed to play a central role. Immunomodulatory agents that decrease immune activation may be useful in the treatment of HIV-1 infection.<h4>Methodology</h4>A randomized, double blind, placebo-controlled pilot study of leflunomide for 28 days was ... Read more >>

PLoS One (PloS one)
[2010, 5(8):e11937]

Cited: 29 times

View full text PDF listing >>



Evidence for translocation of microbial products in patients with idiopathic CD4 lymphocytopenia.

Philip I Lee, Emily J Ciccone, Sarah W Read, Ava Asher, Robert Pitts, Daniel C Douek, Jason M Brenchley, Irini Sereti,

Translocation of microbial products has been described in chronic human immunodeficiency virus (HIV) infection and correlates with activation of the immune system. We investigated the potential translocation of microbial products in idiopathic CD4 lymphocytopenia (ICL), a rare disorder characterized by low CD4 T cell counts in the absence of HIV ... Read more >>

J Infect Dis (The Journal of infectious diseases)
[2009, 199(11):1664-1670]

Cited: 36 times

View full text PDF listing >>



CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients.

Sarah W Read, Richard A Lempicki, Michele Di Mascio, Sharat Srinivasula, Rosanne Burke, William Sachau, Marjorie Bosche, Joseph W Adelsberger, Irini Sereti, Richard T Davey, Jorge A Tavel, Chiung-Yu Huang, Haleem J Issaq, Stephen D Fox, H Clifford Lane, Joseph A Kovacs,

Administration of interleukin (IL)-2 to human immunodeficiency virus (HIV)-infected patients leads to significant increases in CD4 T cell counts. We previously have shown that IL-2 induces increased proliferation and survival of CD4 T cells. Deuterium labeling studies were undertaken to study the relationship between IL-2-induced increases in the CD4 T ... Read more >>

J Infect Dis (The Journal of infectious diseases)
[2008, 198(6):843-850]

Cited: 12 times

View full text PDF listing >>



HIV infection and the gut: scarred for life?

Sarah W Read, Irini Sereti,

J Infect Dis (The Journal of infectious diseases)
[2008, 198(4):453-455]

Cited: 3 times

View full text PDF listing >>



CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation.

Irini Sereti, Peter Sklar, Meena S Ramchandani, Sarah W Read, Vinay Aggarwal, Hiromi Imamichi, Ven Natarajan, Julia A Metcalf, Joseph A Kovacs, Jorge Tavel, Richard T Davey, Rebecca Dersimonian, H Clifford Lane,

<h4>Background</h4>Intermittent interleukin (IL)-2 administration to human immunodeficiency virus (HIV)-infected patients leads to CD4(+) T cell expansions. The factors potentially affecting these expansions were investigated in the present study.<h4>Methods</h4>A matched (for baseline CD4(+) T cell count) case-control study was designed. Nonresponders (NRs) were defined as patients with a <or=10% increase in ... Read more >>

J Infect Dis (The Journal of infectious diseases)
[2007, 196(5):677-683]

Cited: 11 times

View full text PDF listing >>



Decreased CD127 expression on T Cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy.

Sarah W Read, Jeanette Higgins, Julia A Metcalf, Randy A Stevens, Adam Rupert, Martha C Nason, H Clifford Lane, Irini Sereti,

<h4>Background</h4>The interleukin-7 (IL-7)/IL-7 receptor alpha (IL-7Ralpha) system is an important regulator of T-cell homeostasis. We evaluated the IL-7/IL-7Ralpha system in a large cohort of HIV-infected patients, including a subset treated with intermittent IL-2.<h4>Methods</h4>IL-7 serum levels and CD127 (IL-7Ralpha) expression on T cells were evaluated in a cross-sectional study of 36 ... Read more >>

J Acquir Immune Defic Syndr (Journal of acquired immune deficiency syndromes (1999))
[2006, 42(5):537-544]

Cited: 17 times

View full text PDF listing >>



Delayed sample processing leads to marked decreases in measured plasma IL-7 levels.

Sarah W Read, Adam Rupert, Randy Stevens, Angeline O'shea, Irini Sereti,

J Acquir Immune Defic Syndr (Journal of acquired immune deficiency syndromes (1999))
[2006, 42(4):511-512]

Cited: 3 times

View full text PDF listing >>





Advertisement


Disclaimer

0.983 s